| Literature DB >> 10748789 |
Abstract
Repaglinide is a novel oral antidiabetic agent, marking the development of a new class of drugs for type 2 diabetes. This article examines repaglinide and its position in the treatment of type 2 diabetes.Entities:
Mesh：
Substances：
Year: 2000 PMID： 10748789 DOI： 10.12968/hosp.2000.61.2.1275
Source DB: PubMed Journal: Hosp Med ISSN： 1462-3935